What is HC Wainwright’s Estimate for ACRS FY2026 Earnings?

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) – Equities research analysts at HC Wainwright boosted their FY2026 EPS estimates for Aclaris Therapeutics in a report issued on Monday, November 9th. HC Wainwright analyst R. Selvaraju now forecasts that the biotechnology company will post earnings of ($0.57) per share for the year, up from their previous forecast of ($0.61). HC Wainwright has a “Buy” rating and a $16.00 price objective on the stock. The consensus estimate for Aclaris Therapeutics’ current full-year earnings is ($0.59) per share. HC Wainwright also issued estimates for Aclaris Therapeutics’ Q4 2026 earnings at ($0.14) EPS, Q2 2027 earnings at ($0.11) EPS, Q3 2027 earnings at ($0.13) EPS, Q4 2027 earnings at ($0.14) EPS and FY2027 earnings at ($0.51) EPS.

Several other equities analysts have also issued reports on ACRS. Wall Street Zen upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, October 24th. Craig Hallum set a $9.00 price objective on Aclaris Therapeutics in a research report on Wednesday, October 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aclaris Therapeutics in a research report on Monday, September 21st. Wedbush dropped their price objective on Aclaris Therapeutics from $10.00 to $8.00 and set an “outperform” rating for the company in a research note on Wednesday, October 28th. Finally, Canaccord Genuity Group increased their price objective on Aclaris Therapeutics from $10.00 to $13.00 and gave the company a “buy” rating in a research note on Friday, October 30th. Three investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $11.33.

Aclaris Therapeutics Trading Down 2.1%

NASDAQ ACRS opened at $4.15 on Wednesday. Aclaris Therapeutics has a 1-year low of $2.10 and a 1-year high of $6.60. The stock has a 50-day moving average of $4.55 and a 200-day moving average of $4.53. The firm has a market cap of $580.27 million, a PE ratio of -7.16 and a beta of 0.96.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings data on Thursday, November 5th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.04. The firm had revenue of $1.48 million for the quarter, compared to analysts’ expectations of $1.27 million. Aclaris Therapeutics had a negative return on equity of 59.19% and a negative net margin of 1,244.09%.

Hedge Funds Weigh In On Aclaris Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. HighTower Advisors LLC boosted its holdings in shares of Aclaris Therapeutics by 3.5% during the third quarter. HighTower Advisors LLC now owns 225,190 shares of the biotechnology company’s stock worth $1,184,000 after purchasing an additional 7,666 shares during the period. Alps Advisors Inc. increased its holdings in Aclaris Therapeutics by 37.6% during the 3rd quarter. Alps Advisors Inc. now owns 195,036 shares of the biotechnology company’s stock valued at $1,026,000 after purchasing an additional 53,287 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new position in Aclaris Therapeutics during the 3rd quarter valued at about $40,000. Profund Advisors LLC raised its position in Aclaris Therapeutics by 462.3% during the 3rd quarter. Profund Advisors LLC now owns 171,421 shares of the biotechnology company’s stock valued at $902,000 after purchasing an additional 140,935 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its position in Aclaris Therapeutics by 20.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 26,858 shares of the biotechnology company’s stock valued at $142,000 after purchasing an additional 4,630 shares during the last quarter. 98.34% of the stock is owned by institutional investors.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics is a biopharmaceutical company focused on discovering and developing treatments for immuno-inflammatory diseases. Its research programs include small-molecule therapies designed to target pathways involved in inflammation and immune responses. The company’s development portfolio has included candidates for dermatologic and other inflammatory conditions. Aclaris previously developed ESKATA, a topical treatment for raised seborrheic keratoses that received U.S. regulatory approval in 2017.